CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

fluticasone propionate

Last Updated: December 21, 2018
Result type: Reports
Project Number: SR0539-000
Product Line: Reimbursement Review

Generic Name: fluticasone propionate

Brand Name: Aermony RespiClick

Manufacturer: TEVA Canada Innovation

Therapeutic Area: Asthma

Indications: Asthma

Submission Type: Initial

Project Status: Complete

Biosimilar: No

Date Recommendation Issued: December 19, 2018

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

Key Milestones2

Call for patient input postedSeptember 05, 2017
Patient group input closedOctober 25, 2017

- Patient input submission received

Patient input summary sent for review to patient input groupsMarch 29, 2018
Patient group comments on input summary closedApril 06, 2018

- Patient input summary feedback received

Submission receivedOctober 04, 2017
Submission accepted for reviewOctober 19, 2017
Review initiatedFebruary 20, 2018

- Initiation was delayed at the request of the manufacturer

Draft CDR review report(s) sent to applicantMay 16, 2018
Comments from applicant on draft CDR review report(s) receivedJune 08, 2018
Redaction requests from applicant on draft CDR review report(s) receivedJune 15, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantJuly 06, 2018
Canadian Drug Expert Committee (CDEC) meetingJuly 18, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansJuly 31, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedSeptember 13, 2018

- Request for extension to embargo period received from the manufacturer

- Embargo extension request granted

- Reconsideration requested

Applicant's request for reconsideration placed on CDEC agendaDecember 12, 2018
CDEC Final Recommendation issued to applicant and drug plansDecember 19, 2018
CDEC Final Recommendation postedDecember 21, 2018
Final CDR review report(s) and patient input postedJanuary 21, 2019